Trial acronym and/or registration number | Location | Status | Blinding | Control type | N included (N planned) | Mortality % | Planned mortality time pointa | Patient setting | Plasma titer, assay (timing of intervention) | Donor severity (HLA antibody status) |
---|---|---|---|---|---|---|---|---|---|---|
Unpublished | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
LIFESAVER (NCT04374526) | Italy | Recruiting | None | Standard of care | 12 (182) | 16.67% | 28 days | Inpatients with supplemental oxygen | Low titer: ≥ 1:200 S-RBD IgG, EUROIMMUN (Maximum was =  < 14 days after symptom onset) | Mild to moderate (Excluding potentially HLA antibody positive persons) |
RECOVER (EUCTR2020-001632-10-DE) | Germany | Recruiting | None | Standard of care | 90 (174) | 13.33% | 28, 56 and 84 days | Inpatients with supplemental oxygen | Confirmed high-titer: ≥ 1:80, neutralizing antibody assay (No exclusion based on timing of symptom onset) | Mild to severe (Excluding potentially HLA antibody positive persons) |
LACCPT (PACTR202006760881890) | Nigeria | Recruiting | Participant, Care Provider | Placebo (normal saline) | 22 (100) | 59.09% | 3, 5, 7, 9, and 11 days | Inpatients with supplemental oxygen | No minimum cut-off (Maximum was =  < 14 days after symptom onset) | Mild to severe (Excluding potentially HLA antibody positive persons) |
CPC-SARS (NCT04405310) | Mexico | Recruiting | Participant, Care Provider | Placebo (hartmann plus albumine) | 42 (80) | 28.57% | 15 days | Inpatients with supplemental oxygen | Confirmed high-titer: > 1000 S-RBD IgG, > 1:32 neutralizing, separate in-house assays (Maximum was > 14 days after symptom onset) | Mild to moderate (Excluding potentially HLA antibody positive persons) |
NCT04442191 | United States | Recruiting | Participant, Care Provider | Placebo (fresh frozen plasma) | 14 (50) | 7.14% | 28Â days | Inpatients with supplemental oxygen | Low-titer: S-RBD IgG, Abbott Architect IgG (No exclusion based on timing of symptom onset) | NA (Not excluding potentially HLA antibody positive persons) |
NCT04385199 | United States | Recruiting | None | Standard of care | 30 (30) | 16.67% | NR | Inpatients with supplemental oxygen | No minimum cut-off (No exclusion based on timing of symptom onset) | NA (NA) |
NCT04403477 (NCT04403477)b | Bangladesh | Recruiting | None | Standard of care | 30 (60) | 18.33% | 28 days | Inpatients with supplemental oxygen | Low titer: ≥ 1:160 S-RBD IgG, EUROIMMUN (Maximum was =  < 14 days after symptom onset) | Moderate to severe (Excluding potentially HLA antibody positive persons) |
PLACO-COVID (NCT04428021) | Italy | Active, not recruiting | Participant, Care Provider, Outcomes Assessor | Standard of care | 120 (180)c | 15.83% | 30Â days | Inpatients with supplemental oxygen | No minimum cut-off (No exclusion based on timing of symptom onset) | Mild to severe (Excluding potentially HLA antibody positive persons) |
REMAP-CAP (NCT02735707) | International | Terminated | None | Standard of care | 2014 (N/A) | 34.26% | 90 days | ICU | Confirmed high-titer: ≥ 1:100 neutralizing or equivalent. In the UK: EUROIMMUN S/C ≥ 6 (No exclusion based on timing of symptom onset) | NA (Excluding potentially HLA antibody positive persons) |
ASCOT (NCT04483960) | Australia and New Zealand | Terminated | None | Standard of care | 33 (N/A) | 9.09% | 28 days | Inpatients with or without supplemental oxygen | Confirmed high-titer: ≥ 1:80, neutralizing assay by Walker et al. (2021) (Maximum was =  < 14 days after symptom onset) | NA (Excluding potentially HLA antibody positive persons) |
Co-CLARITY (NCT04567173) | Philippines | Recruiting | None | Standard of care | 25 (136) | 0.00% | 28 days | Inpatients with or without supplemental oxygen | Low titer: Ortho VITROS S/C ≥ 5 (Maximum was =  < 14 days after symptom onset) | Moderate to severe (Excluding potentially HLA antibody positive persons) |
NCT04528368 | Brazil | Recruiting | None | Standard of care | 16 (60) | 0.00% | 7, 10, 14, 21 and 28 days | Inpatients with or without supplemental oxygen | Low titer: ≥ 1:320 S-RBD IgG, in-house assay (Maximum was =  < 14 days after symptom onset) | NA (Excluding potentially HLA antibody positive persons) |
CAPSID (NCT04433910) | Germany | Recruiting | None | Standard of care | 5 (106) | 0.00% | 21, 35 and 60Â days | ICU | No minimum cut-off (No exclusion based on timing of symptom onset) | NA (Not excluding potentially HLA antibody positive persons) |
PERUCONPLASMA (NCT04497324) | Peru | Recruiting | None | Standard of care | 25 (100) | 16.00% | 30 days | Inpatients with supplemental oxygen | Confirmed high-titer: EUROIMMUN S/C > 5.0 (No exclusion based on timing of symptom onset) | Moderate to severe (Excluding potentially HLA antibody positive persons) |
NCT04332835 | Colombia | Completed | Outcome Assessor | Standard of care | 100 (92) | 8.00% | 7, 14 and 28 days | Inpatients with supplemental oxygen | Confirmed high-titer: IgG ≥ 1/3200 and IgA ≥ 1/800 by EUROIMMUN. All transfused plasma presented neutralizing antibodies ≥ 1/256 (No exclusion based on timing of symptom onset) | Moderate to severe (Excluding potentially HLA antibody positive persons) |
CONFIDENT (NCT04558476) | Belgium | Recruiting | None | Standard of care | 301 (500) | 31.89% | 28 and 90 days | ICU | Confirmed high-titer: ≥ 1:320 neutralizing, in-house assay (No exclusion based on timing of symptom onset) | NA (Excluding potentially HLA antibody positive persons) |
PC/COVID-19 (NCT04366245) | Spain | Completed | None | Standard of care | 41 (72) | 2.44% | 14 and 28 days | Inpatients with supplemental oxygen | Low titer: Vircell SL (Spain) test, correlates to ≥ 1:320 S-RBD IgG (Maximum was =  < 14 days after symptom onset) | Mild to moderate (Excluding potentially HLA antibody positive persons) |
COP-COVID-19 (NCT04358783) | Mexico | Recruiting | Participant, Care Provider | Standard of care | 31 (30) | 35.48% | 14 days | Inpatients with supplemental oxygen | Low titer: S/C ≥ 3, Abbott's chemiluminescent microparticle immunoassay for the qualitative detection of IgG (Maximum was =  < 14 days after symptom onset) | NA (Excluding potentially HLA antibody positive persons) |
NCT04600440 | Sweden | Terminated | None | Standard of care | 31 (100) | 16.13% | 90 days | Inpatients with supplemental oxygen | Confirmed high-titer: ≥ 1:40 neutralizing, in-house assay (No exclusion based on timing of symptom onset) | Mild to moderate (Excluding potentially HLA antibody positive persons) |
CCAP-2 (NCT04345289) | Denmark | Terminated | Participant, Care Provider, Outcome Assessor | Placebo (normal saline) | 144 (1,100) | 11.11% | 7, 14, 21, 28 and 90Â days | Inpatients with or without supplemental oxygen | Other titer leveld (No exclusion based on timing of symptom onset) | NA (Excluding potentially HLA antibody positive persons) |
Published | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
ChiCTR2000029757 | China | Terminated | None | Standard of care | 103 (200) | 19.42% | 28 days | Inpatients with supplemental oxygen | Confirmed high-titer: ≥ 1:640 S-RBD IgG, in-house assay (NA) | NA (NA) |
NCT04342182 | Netherlands | Terminated | None | Standard of care | 86 (426) | 19.77% | 60 days | Inpatients with or without supplemental oxygen | Low titer: ≥ 1:400 S-RBD IgG, assay missing (No exclusion based on timing of symptom onset) | NA (Excluding potentially HLA antibody positive persons) |
NCT04392414 | Russia | Completed | None | Placebo (fresh frozen plasma) | 66 (60) | 6.06% | 30 days | Inpatients with or without supplemental oxygen | Confirmed high-titer: ≥ 1:1000 S-RBD IgG, in-house assay (Maximum was =  < 14 days after symptom onset) | Moderate to severe (Not excluding potentially HLA antibody positive persons) |
ConPlas-19 (NCT04345523) | Spain | Terminated | None | Standard of care | 81 (278) | 4.94% | 29 days | Inpatients with or without supplemental oxygen | Confirmed high-titer: > 1:80, neutralizing assay (Maximum was =  < 14 days after symptom onset) | NA (NA) |
PLACID (CTRI/2020/04/024775) | India | Completed | None | Standard of care | 464 (452) | 14.01% | 28Â days | Inpatients with supplemental oxygen | No minimum cut-off (No exclusion based on timing of symptom onset) | Mild to moderate (Excluding potentially HLA antibody positive persons) |
ILBS-COVID-02 (NCT04346446) | India | Completed | None | Placebo (fresh frozen plasma) | 31 (40) | 3.23% | 28Â days | Inpatients with supplemental oxygen | No minimum cut-off (No exclusion based on timing of symptom onset) | NA (Excluding potentially HLA antibody positive persons) |
NCT04356534 | Bahrain | Completed | None | Standard of care | 40 (40) | 7.50% | 28 days | Inpatients with supplemental oxygen | No minimum cut-off (Maximum was =  < 14 days after symptom onset) | Moderate to severe (Excluding potentially HLA antibody positive persons) |
PLASM-AR (NCT04383535) | Argentina | Completed | Participant, Care Provider | Placebo (normal saline) | 333 (333) | 11.11% | 30 days | Inpatients with or without supplemental oxygen | Confirmed high-titer: ≥ 1:800 S-RBD IgG, COVIDAR IgG test (No exclusion based on timing of symptom onset) | Mild to moderate (Excluding potentially HLA antibody positive persons) |
PICP19 (CTRI/2020/05/025209) | India | Completed | None | Standard of care | 80 (80) | 30.00% | 30 days | Inpatients with supplemental oxygen | No minimum cut-off (Maximum was =  < 14 days after symptom onset) | NA (Excluding potentially HLA antibody positive persons) |
NCT04479163 | Argentina | Terminated | Participant, Care Provider | Placebo (normal saline) | 160 (210) | 3.75% | 25 days | Outpatients | Confirmed high-titer: > 1:1000 (COVIDAR IgG, Instituto Leloir, Argentina) (Maximum was =  < 14 days after symptom onset) | NA (NA) |
RECOVERY Trial (NCT04381936) | United Kingdom | Terminated | None | Standard of care | 11,558 (N/A) | 24.28% | 28 days | Inpatients with or without supplemental oxygen | Confirmed high-titer: ≥ 1:100 neutralizing (EUROIMMUN IgG ELISA S/C ≥ 6.0) (No exclusion based on timing of symptom onset) | NA (Excluding potentially HLA antibody positive persons) |
NCT04359810 | United States | Completed | Participant, Outcomes Assessor | Placebo (fresh frozen plasma) | 223 (219) | 16.59% | 28 days | Inpatients with or without supplemental oxygen | Low titer: ≥ 1:400 S-RBD IgG, in-house assay (No exclusion based on timing of symptom onset) | NA (NA) |
IRCT20200310046736N1e | Iran | Completed | Participant, Outcome Assessor | Standard of care | 62 (62) | 12.90% | 60 days | Inpatients with supplemental oxygen | No minimum cut-off (Maximum was =  < 14 days after symptom onset) | NA (Excluding potentially HLA antibody positive persons) |